ProPSA, un nuevo biomarcador para la detección y el manejo del cáncer de próstata

Catalona, 1998, Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: A prospective multicenter clinical trial, JAMA, 279, 1542, 10.1001/jama.279.19.1542 Mikolajczyk, 2002, Free prostate-specific antigen in serum is becoming more complex, Urology, 59, 797, 10.1016/S0090-4295(01)01605-3 Mikolajczyk, 2003, Pro PSA: A more cancer specific form of prostate specific antigen for the early detection of prostate cancer, Keio J Med, 52, 86, 10.2302/kjm.52.86 Sokoll, 2003, Proenzyme psa for the early detection of prostate cancer in the 2.5-4.0ng/ml total psa range: Preliminary analysis, Urology, 61, 274, 10.1016/S0090-4295(02)02398-1 Catalona, 2003, Serum pro prostate specific antigen improves cancer detection compared to free and complexed prostate specific antigen in men with prostate specific antigen 2 to 4ng/ml, J Urol, 170, 2181, 10.1097/01.ju.0000095460.12999.43 Khan, 2003, Evaluation of proprostate specific antigen for early detection of prostate cancer in men with a total prostate specific antigen range of 4.0 to 10.0ng/ml, J Urol, 170, 723, 10.1097/01.ju.0000086940.10392.93 Mikolajczyk, 2004, Proenzyme forms of prostate-specific antigen in serum improve the detection of prostate cancer, Clin Chem, 50, 1017, 10.1373/clinchem.2003.026823 Khan, 2004, Clinical utility of proPSA and “benign” PSA when percent free PSA is less than 15%, Urology, 64, 1160, 10.1016/j.urology.2004.06.033 Stephan, 2006, A (-5, -7) proPSA based artificial neural network to detect prostate cancer, Eur Urol, 50, 1014, 10.1016/j.eururo.2006.04.011 Filella, 2007, Usefulness of proprostate-specific antigen in the diagnosis of prostate cancer, Anticancer Res, 27, 607 Roddam, 2005, Use of prostate-specific antigen (PSA) isoforms for the detection of prostate cancer in men with a PSA level of 2-10ng/ml: Systematic review and meta-analysis, Eur Urol, 48, 386, 10.1016/j.eururo.2005.04.015 Slawin, 2005, BPSA: A novel serum marker for benign prostatic hyperplasia, Rev Urol, 7, S52 Semjonow, 2010, Pre-analytical in-vitro stability of [–2]proPSA in blood and serum, Clin Biochem, 43, 926, 10.1016/j.clinbiochem.2010.04.062 Filella, 2012, Evaluation of [–2] proPSA and Prostate Health Index (phi) for the detection of prostate cancer: A systematic review and meta-analysis, Clin Chem Lab Med, 15, 1, 10.1515/cclm-2012-0410 Sokoll, 2010, A prospective, multicenter, National Cancer Institute Early Detection Research Network study of [–2]proPSA: Improving prostate cancer detection and correlating with cancer aggressiveness, Cancer Epidemiol Biomarkers Prev, 19, 1193, 10.1158/1055-9965.EPI-10-0007 Le, 2010, [–2]Proenzyme prostate specific antigen is more accurate than total and free prostate specific antigen in differentiating prostate cancer from benign disease in a prospective prostate cancer screening study, J Urol, 183, 1355, 10.1016/j.juro.2009.12.056 Catalona, 2011, A multicenter study of [–2]pro-prostate specific antigen combined with prostate specific antigen and free prostate specific antigen for prostate cancer detection in the 2.0 to 10.0ng/ml prostate specific antigen range, J Urol, 185, 1650, 10.1016/j.juro.2010.12.032 Guazzoni, 2011, Prostate-specific antigen (PSA) isoform p2PSA significantly improves the prediction of prostate cancer at initial extended prostate biopsies in patients with total PSA between 2.0 and 10ng/ml: results of a prospective study in a clinical setting, Eur Urol, 60, 214, 10.1016/j.eururo.2011.03.052 Lughezzani, 2012, Development and internal validation of a Prostate Health Index based nomogram for predicting prostate cancer at extended biopsy, J Urol, 188, 1144, 10.1016/j.juro.2012.06.025 Guazzoni, 2012, Preoperative prostate-specific antigen isoform p2PSA and its derivatives, %p2PSA and prostate health index, predict pathologic outcomes in patients undergoing radical prostatectomy for prostate cancer, Eur Urol, 61, 455, 10.1016/j.eururo.2011.10.038 Stephan, 2009, A [–2]proPSA-based artificial neural network significantly improves differentiation between prostate cancer and benign prostatic diseases, Prostate, 69, 198, 10.1002/pros.20872 Makarov, 2009, Pro-prostate-specific antigen measurements in serum and tissue are associated with treatment necessity among men enrolled in expectant management for prostate cancer, Clin Cancer Res, 15, 7316, 10.1158/1078-0432.CCR-09-1263 Jansen, 2010, Prostate-specific antigen (PSA) isoform p2PSA in combination with total PSA and free PSA improves diagnostic accuracy in prostate cancer detection, Eur Urol, 57, 921, 10.1016/j.eururo.2010.02.003 Lazzeri, 2012, Serum index test %[–2]proPSA and Prostate Health Index are more accurate than prostate specific antigen and %fPSA in predicting a positive repeat prostate biopsy, J Urol, 188, 1137, 10.1016/j.juro.2012.06.017